A Unique Mammalian Suspension Technology Enhances Scalable rAAV Production with Pro10 Cell Line

The Pro10™ cell line is a new technology that aims to improve the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology allows for scalable and robust production of rAAVs, addressing the challenges of large-scale manufacturing in AAV gene therapies.

The Pro10™ cells have been fully characterized and licensed for gene therapy development by other biopharma companies. Viralgen utilizes these cells as the foundation for a robust and scalable rAAV vector manufacturing process, successfully scaling them up to 2000L. They exhibit consistent and reproducible cell growth rates in both small and large-scale bioreactors, producing different AAV serotypes with similar productivity.

The HEK293 derived animal component-free suspension Pro10™ cell line is described in full in the PDF, highlighting its ability to reduce process development time and costs. This innovative technology is a promising advancement in the field of gene therapy manufacturing, offering a solution to the challenges faced in large-scale production of AAV vectors.

By Aiden Johnson

As a content writer at newspoip.com, I have a passion for crafting engaging and informative articles that captivate readers. With a keen eye for detail and a knack for storytelling, I strive to deliver content that not only informs but also entertains. My goal is to create compelling narratives that resonate with our audience and keep them coming back for more. Whether I'm delving into the latest news topics or exploring in-depth features, I am dedicated to producing high-quality content that informs, inspires, and sparks curiosity.

Leave a Reply